Stern Y, Mayeux R, Ilson J, Fahn S, Cote L
Neurology. 1984 Feb;34(2):201-4. doi: 10.1212/wnl.34.2.201.
Pergolide mesylate, a long-acting dopamine agonist, is effective in treating Parkinson's disease. Behavioral change is said to be one adverse effect. We therefore studied 19 parkinsonian patients with neuropsychological tests before and after initiating pergolide therapy. Intellectual and behavioral changes were also monitored clinically for up to 2 years. There was no decline in performance on the neuropsychological tests. Six patients had transient psychiatric or intellectual changes that were controlled by reducing drug dosage. These changes were similar to those seen with other dopamine agonists.
甲磺酸培高利特是一种长效多巴胺激动剂，对治疗帕金森病有效。行为改变据说是其一种不良反应。因此，我们在开始培高利特治疗前后，用神经心理学测试研究了19例帕金森病患者。还对智力和行为变化进行了长达2年的临床监测。神经心理学测试的表现没有下降。6例患者出现短暂的精神或智力变化，通过减少药物剂量得到控制。这些变化与其他多巴胺激动剂引起的变化相似。
